Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response?
alopecia areata
diphenylcyclopropenone
response rate
sensitization
topical immunotherapy
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
09
08
2021
received:
16
07
2021
accepted:
29
08
2021
pubmed:
1
9
2021
medline:
1
4
2022
entrez:
31
8
2021
Statut:
ppublish
Résumé
Immunotherapy by diphenylcyclopropenone (DPCP) is generally started with 2% DPCP sensitization, however in recent years studies have questioned the necessity of sensitization that may cause patients severe reactions and troubles at the onset of therapy. The purpose of the present study was to evaluate the association between the severity of initial reaction to 2% DPCP sensitization in AA patients and clinical response. In this retrospective study, 110 AA patients who continued therapy for at least 6 months were enrolled. Hair loss and hair regrowth rates were calculated based on the Severity of Alopecia Tool (SALT) scoring system. Initial reaction to 2% DPCP sensitization after 2 weeks was graded as negative reaction (absence of any reaction), doubtful reaction (mild erythema, pruritus, and irritation for minutes after test), weak (erythema, mild edema, and scaling), and strong to extreme reaction (vesicles, bullae, ulcer, and discharge). The degrees of the initial reaction to 2% DPCP after 2 weeks were negative reaction 13 (11.81%), doubtful reaction 40 (36.36%), weak reaction 33 (30%), and strong to extreme reaction 24 (21.81%). Patients were divided into two groups: (A) patients with less than 12-month therapy (75 of 110), (B) patients with more than 12-month therapy (35 of 110). Initial reaction to 2% DPCP sensitization was not correlated with hair regrowth rate in either group (group A: Spearman's rho = 0.194, p = 0.095; group B: Spearman's rho = 0.063 p = 0.720). After 12-month treatment with DPCP, hair regrowth rate was significantly greater than 6-months therapy (group A: 17.03 ± 37.78, group B: 49.26 ± 36.34; p = 0.003). The severity of hair loss at the onset of treatment was significantly associated with the response rate in both groups (p-value <0.002). Based on our results, it is the initial severity of the disease and not the initial reaction to 2% DPCP sensitization that predicts the clinical response to DPCP immunotherapy.
Substances chimiques
Cyclopropanes
0
diphenylcyclopropenone
I7G14NW5EC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15118Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Amin SS, Sachdeva S. Alopecia areata: an update. J Pak Assoc Dermatol. 2016;23(2):209-220.
Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675-682.
Villasante Fricke AC, Miteva M. Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol. 2015;24:8403-8397.
Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64-69.
Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. 2018;78(1):15-24.
Happle R, Hausen BM, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol. 1983;63:49-52.
Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549-566.
Vedak P, Kroshinsky D. Squaric acid sensitization is not required for response in the treatment of alopecia areata. J Am Acad Dermatol. 2015;73(3):471-476.
Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines-Part II. J Am Acad Dermatol. 2004;51(3):440-447.
Lazzarini R, Duarte I, Ferreira AL. Patch test. An Bras Dermatol. 2013;88(6):879-888.
El-Zawahry BM, Bassiouny DA, Khella A, Zaki NS. Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol. 2010;24(3):264-269.
Ohlmeier MC, Traupe H, Luger TA, Böhm M. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata-a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol. 2012;26(4):503-507.
Choe SJ, Lee S, Pi LQ, et al. Subclinical sensitization with diphenylcyclopropenone is sufficient for the treatment of alopecia areata: retrospective analysis of 159 cases. J Am Acad Dermatol. 2018;78(3):515-521.
Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol. 2005;5:6.
Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. 2016;41(4):352-358.
Borges AS, Brasileiro A, Ramos Pinheiro R, Lencastre A. Topical immunomodulation with diphenlycyclopropenone for alopecia areata. J Portuguese Soc Dermatol Venereol. 2019;77(2):139-142.
Zerbinati N, Esposito C, D'este E, Calligaro A, Valsecchi R. Topical immunotherapy of alopecia areata: a large retrospective study. Dermatol Ther (Heidelb). 2018;8(1):101-110.
Nasimi M, Abedini R, Ghandi N, Seirafi H, Mehdizade MS, Tootoonchi N. Topical immunotherapy with diphenylcyclopropenone in patients with alopecia areata: a large retrospective study of 757 patients. Dermatol Ther. 2020;33:e13808.
Lee S, Kim BJ, Lee YB, Lee WS. Hair regrowth outcomes of contact immunotherapy for patients with alopecia areata: a systematic review and meta-analysis. JAMA Dermatol. 2018;154(10):1145-1151.
Case PC, Mitchell AJ, Swanson NA, Vanderveen EE, Ellis CN, Headington JT. Topical therapy of alopecia areata with squaric acid dibutylester. J Am Acad Dermatol. 1984;10:447-450.
Yoshimasu T, Furukawa F. Modified immunotherapy for alopecia areata. Autoimmun Rev. 2016;15(7):664-667.
Dall'oglio F, Nasca MR, Musumeci ML, et al. Topical immunomodulator therapy with squaric acid dibutylester is an effective treatment for severe alopecia areata. J Dermatolog Treat. 2005;16:10-14.
Chiang KS, Mesinkovska NA, Piliang MP, Bergfeld WF. Clinical efficacy of diphenylcyclopropenone in alopecia areata: retrospective data analysis of 50 patients. J Investig Dermatol Symp Proc. 2015;17(2):50-55.